Nav: Home

China unlikely to curb fentanyl exports in short-term

May 15, 2019

Strict policies traditionally embraced by Asian nations to discourage illicit drug use are beginning to change, with a few nations adopting alternative approaches while other nations are taking an even harder line against drugs, according to a new RAND Corporation report.

Thailand is on the forefront of Southeast Asian nations that are reconsidering longstanding policies, moving to adopt greater harm reduction, approving the use of medical cannabis and easing restrictions on the traditional use of the substance kratom.

Meanwhile, some other nations -- most visibly represented by the Philippines -- are adopting even harsher policies on illicit drugs, including violent repression of drug distribution and use.

"Asian nations have long espoused the goal of a drug-free society, imposing harsh criminal penalties and even the death penalty on those involved with illicit drugs," said Bryce Pardo, lead author of the report and a policy analyst at RAND, a nonprofit research organization. "So it is surprising to see some Asian nations begin to go in a different direction and consider more-progressive policies."

The RAND report also dissects China's role as a focal point in the global supply of fentanyl, a powerful synthetic opioid that is responsible for a growing number of fatal drug overdoses in the U.S.

The report outlines the rapid rise of the drug industry in China, where there are now more than 5,000 pharmaceutical manufacturers and hundreds of thousands of chemical companies. While the industry is a leading source of many legitimate chemicals and pharmaceutical ingredients, its growth has made it easier for some companies to avoid regulations.

China's central government has promised to crack down on fentanyl manufacturers, but enforcement of such policies is typically done at the provincial level, where there is little infrastructure in place to regulate the drug and chemical industries.

"China's leaders recognize that they have a problem and appear committed to seeking solutions," Pardo said. "But it is unlikely that they can contain the illicit production and distribution of fentanyl in the short term because enforcement mechanisms are lacking. Producers are quick to adapt, impeding Chinese law enforcement's ability to stem the flow to global markets."

Thailand's shift from harsh drug policies toward evidence-based treatment and reduced punishment appears to be motivated by the heavy burden previous policies have had on its prison system and an alarming increase in disease transmission related to needle-sharing.

In 2016, about 70 percent of Thailand's 320,000 prisoners were incarcerated for drug offences, including many for consumption-related violations. The nation has begun to move toward voluntary outpatient treatment and has experimented with needle-exchange programs to address disease transmission.

The report notes that the illicit production and use of opioids and amphetamine-type substances are the greatest concern across Asia. There also are reports of rising trafficking and use of new psychoactive substances and ketamine.

But one challenge facing Asian nations is a shortage of reliable information about drug use, which is key to assessing the size of the problem and judging the influence of policies.

"As in many countries, there is tremendous imprecision in the data available on the prevalence of drug use in Asia and the amount of money spent on these substances," said Beau Kilmer, a co-author of the report and co-director of the RAND Drug Policy Research Center. "Policy shifts are occurring and these data gaps will make it difficult to evaluate the consequences of these changes in the near and longer term."
-end-
Funding for the study was provided by the RAND Center for Asia Pacific Policy, which is supported by donations from its advisory board.

The report, "Contemporary Asian Drug Policy: Insights and Opportunities for Change," is available at http://www.rand.org. Another author of the study is Wenjing Huang.

The research was conducted within the RAND Center for Asia Pacific Policy, which improves policy by providing decisionmakers and the public with rigorous, objective, cutting-edge research on critical policy challenges facing Asia and U.S.-Asia relations.

RAND Corporation

Related Drugs Articles:

Using drugs for different diseases than initially intended for
Thousands of drugs have the potential to be effective against other diseases than they were developed for.
Virtual development of real drugs
systemsDock is a new, free on-line resource that makes screening for drugs faster and more accurate.
Migraine drugs underused
New research shows that more migraines could be safely treated with drugs that are known to constrict blood vessels.
Why cancer drugs can't take the pressure
A major reason why cancer drugs fail is that they cannot penetrate the high-pressure environment of solid tumors.
Designing better drugs
A new strategy for engineering protein fusions -- to make specific cell-targeted drugs without side effects -- could enable a safer, more potent class of protein drugs.
Why synthetic drugs are as scary as you think (video)
Synthetic drugs such as 'bath salts,' 'K2' or 'Spice' have made unsettling headlines lately, with reports of violent, erratic behavior and deaths after people have used the substances.
Using old drugs to treat new viruses
A group of drugs already in everyday use to treat psychosis or depression may also be used to defeat deadly and emerging viruses, according to new research led by the University of Leeds.
'Metal' drugs to fight cancer
What is the mechanism of action of metal-based chemotherapy drugs (the most widely used for treating common cancers like testicular or ovarian cancer)?
Using superlatives in the media for cancer drugs
The use of superlatives to describe cancer drugs in news articles as 'breakthrough,' 'revolutionary,' 'miracle' or in other grandiose terms was common even when drugs were not yet approved, had no clinical data or not yet shown overall survival benefits, according to an article published online by JAMA Oncology.
Seeking a better way to design drugs
With a three-year, $346,000 award from the National Institutes of Health, a research team at Worcester Polytechnic Institute.

Related Drugs Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".